CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
picoplatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00116610
NCT00116610Phase 2Completed
CompareCT.gov

A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer

Poniard Pharmaceuticals·interventional·Posted Jun 30, 2005·Updated Jan 21, 2009

In Brief

A Phase 2 clinical trial evaluating picoplatin for Small Cell Lung Cancer. Completed, across 55 sites in 3 countries.

Detailed Summary

This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesCanada, Russia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 30, 2005
Enrollment StartJun 1, 2005
Primary CompletionMar 1, 2007
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 21.0 years ago

Interventions

picoplatindrug